ORIGINAL ARTICLE

Blindness Reversal with KJ'S Nano Eye Pad

K. Jagadeesan¹, Kesav Jagadeesan², K. Mohandas³, Mohan Rajan⁴, Aruninbaraj⁵, S. Lakshita⁶

Abstract

Retinitis pigmentosa (RP) is a group of inherited disorders affecting 1 in 3000-7000 people and characterized by abnormalities of the photoreceptors of the retina (rods and cones) [1]. Retinitis pigmentosa has been associated with more than 40 genes, most of which are expressed in photoreceptors or the retinal pigment epithelium. In autosomal recessive retinitis pigmentosa, both the parents of the patient carry mutated gene of retinitis pigmentosa. Even though the parents carry the gene they themselves do not exhibit symptoms. Their children have a 25% chance of being affected by inheriting a mutated copy from each of their parents [2]. Research and development work is on for gene therapy elsewhere. In this study we are attempting to reverse the Retinitis Pigmentosa with the help of nanoenergy.

Keywords: Retinitis Pigmentosa, gene therapy.

¹Chairman and Managing Director, ² Surgeon, ³Surgeon, ⁵Research Scholar, K. J. Hospital Research and Postgraduate Centre, Chennai, Tamil Nadu, India

⁴Ophthalmologist, Rajan Eye Care Hospital Pvt. Ltd., Chairman & Medical Director, Chennai, Tamil Nadu, India

⁶PG, K. J.Hospital Private Limited, Chennai, Tamil Nadu, India **Corresponding Author:** Dr. K. Jagadeesan, Chairman, K. J. Research Foundation, Managing Director, K. J. Hospital Research and Postgraduate Centre, Chennai, TamilNadu, India

E-Mail: drkjagadeesan@gmail.com Received: 14th March 2023 Accepted: 27th March 2023 **How to Cite this Article**: Jagadeesan K, Jagadeesan Kesav, Mohandas K, Rajan M, Aruninbaraj, Lakshita S. Blindness reversal with KJ'S Nano eye pad. J Int Med Sci Acad 2023;36(2):154-155.

Access this article online: www.imsaonline.com



Introduction

Retinitis pigmentosa (RP) is a disease condition that was first identified and named by Dr. Donders in 1857. Researchers have identified several major types of nonsyndromic retinitis pigmentosa, which are usually differentiated by their pattern of inheritance: autosomal dominant, autosomal recessive or X-linked. Retinitis pigmentosa sometimes happens with syndromes affecting other organs and tissues. These forms of the disease are described as syndromic. Usher syndrome is the most common form of syndromic retinitis pigmentosa and involves hearing loss and vision loss starting at a young age. Retinitis pigmentosa is also a feature of several other genetic syndromes, including Bardet-Biedl syndrome; Refsum disease; and neuropathy, ataxia, and retinitis pigmentosa (NARP) [1].

Materials and Methods

52 years old physical Instructor in one of the city colleges. He developed blindness about 19 years ago. He is an active person and he was in good health, he developed sudden dropped in vision. This retinitis pigmentosa patient was directed to us by our previous patient who has recovered from autism with the application of nanotechnology.

We have applied same Nano principle and applying a Nano eye pad. The Eye pad was made on the basis of nanoenergy boosting. We advised him to continuously wear the eye pad (shown in the Figure 1) for 2 months. Before starting the treatment, we assess his intraocular pressure is normal, no pupillary reaction and light perception are found to be negative. He did not show any change in the other clinical parameters. He was treated at all the major ophthalmic centre in the city. He is recommended for permanent disability pension by all the centres.




Figure 1


Contents of the journal except advertisements are protected under Indian and International copyrights. No part of the journal shall be reproduced or transmitted in any form or by any means including electronic, mechanical, photocopying and microfilm without prior permission from the Editor-in-chief. However, individual researchers, medical students and practicing doctors are permitted to photocopy or print single articles for non-profit activities such as teaching, research and health education provided the number of copies do not exceed 5. JIMSA subscribes to the ethical standards of medical publishing promulgated by International Committee of Medical Journal Editors (ICMJE) and World Association of Medical Editors (WAME). JIMSA periodically changes its policies in resonance with updates of these organizations. Updated policies of these organizations can be accessed from WAME: http://www.wame.org

Result & Discussion


Two months after continuously wearing the Nano eye pad when we opened we removed the eye pad we found him to approach bright light, the pupillary reaction noted then subsequently after the month he could appreciate light 300 meters away (Distant vision). He underwent cataract surgery on the left eye at another centre. Instantly the right eye found to show calcific cataract which was attended subsequently.




NORMAL




Retinitis Pigmentosa



14.06.2023 After 2 months light perception and Pupillary reaction in the eye.



05.07.2023 After one week appreciate light 300 meters away (Distant vision)



27.07.2023 Retinitis Pigmentosa almost disappear normal retina has comback

They were helping us in the follow-up and progress. Two weeks he did not use Nanotheraphy. There after he continued the nanotheraphy. And it was found the fundus picture shows the Retinitis pigmentosa almost disappear normal retina has come back. We have made an attempt to overcome the blindness cause the genetically transmitted genomic condition by the application of appropriate Nano therapy with the right energy choice of nanoparticles.

Conclusion

We hope very soon he will start reading alphabets. We can have a permanent solution for this incurable condition. With more number of cases and enough experience in the field I am sure we will be able to reverse retinitis pigmentosa blindness.

Conflict of Interest:	All authors declare no COI
Ethics:	There is no ethical violation as it is based on voluntary anonymous interviews
Funding:	No external funding
Guarantor:	Dr. K. Jagadeesan will act as guarantor of this article on behalf of all co-authors.

References

- Stefano Ferrari, Enzo Di Iorio, Vanessa Barbaro, Diego Ponzin, Francesco S Sorrentino, Francesco Parmeggiani. Retinitis Pigmentosa: Genes and Disease Mechanisms. 2011 Jun; 12(4):238-249.
- Verbakel SK, van Huet RAC, Boon CJF, den Hollander AI, Collin RWJ, Klaver CCW, Hoyng CB, Roepman R, Klevering BJ. Non-syndromic retinitis pigmentosa. Prog Retin Eye Res. 2018 Sep;66:157-186.

